March 17, 2017: A landmark day for PCSK9 inhibition

Click here to forward this email to a colleague

March 17, 2017: A landmark day for PCSK9 inhibition

Over 20 years since the 4S trial, ACC.2017 was the setting for another landmark cholesterol lowering trial - FOURIER.

Experts from the PCSK9 Forum Editorial Board give their views.



Prof Henry Ginsberg: Data needed on the diabetes subgroup in FOURIER	Prof Philip Barter: How do we translate the FOURIER data to clinical practice?	Prof John Chapman: FOURIER - Why was there no significant effect on CV mortality?	Prof John Chapman: FOURIER endpoint data	PCSK9 Forum Editor Professor Philip Barter discusses FOURIER	Prof Raul Santos: SPIRE trials with bococizumab

See all the reports & videos from ACC here »

Kausik Ray, Professor of Public Heath (Imperial College, London, UK) analyses FOURIER, SPIRE-2 and ODYSSEY outcomes.

Watch the video here »

We are reporting in real time from ACC
Tell your colleagues to join us and receive our reports
Click here to forward this email

Like us on Facebook

For the latest updates, PCSK9 news and analysis.

Hot topics, news and conference reports.

YouTube Channel

For videos, interviews and webcasts from leading experts.


	Our popular therapeutic guide Third edition coming soon updated with the latest information discussing the biology and therapeutic potential of PCSK9 inhibition. Read online » Download now » Forward to colleagues »

Questions & Answers

Read the full answer and other questions on the PCSK9 Forum »

Educational Partners
and Supporters